Skip to Main Content

The Food and Drug Administration is delaying its decision on Biogen’s closely watched Alzheimer’s drug aducanumab, requesting more evidence that the treatment can slow the cognitive decline associated with the disease, the company said Friday.

The FDA had promised to render a decision on the approval of aducanumab by March 7. The process is now being extended by three months to June 7, the company said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.